Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synchrony Financial (SYF) vs GeneDx Holdings Corp (WGS) Price & Performance

Synchrony FinancialTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Synchrony Financial vs GeneDx Holdings Corp — how do they compare? Synchrony Financial trades at $78.68 (market cap $25.53B), while GeneDx Holdings Corp trades at $82.34 (market cap $2.44B). The key difference: Synchrony Financial is far larger — about 10.5× GeneDx Holdings Corp's market cap, and Synchrony Financial pays a 1.73% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

SYFWGS
Market Cap
$25.53B$2.44B
Sector
FinancialsTechnology
52-Week High
$88.47$167.51
52-Week Low
$63.78$34.51
Dividend Yield
1.73%
Enterprise Value
$2.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synchrony Financial

Synchrony Financial (SYF) trades at $78.25, up 0.08% on the day, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The stock shows robust fundamentals with a P/E of 8.05, net income margin of 23.4%, and consistent revenue around $15.0B. Recent news highlights partnerships like CareCredit with Stripe and aggressive share buybacks, while analyst consensus is strongly positive with a $86.33 price target.

The outlook for SYF is favorable due to undervaluation, earnings growth, and shareholder returns via dividends and buybacks. Risks include economic sensitivity to consumer spending and rising expenses. With no sell ratings from analysts and institutional confidence, the stock presents a solid opportunity for value-oriented investors seeking financial sector exposure.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.

Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS